Search Results - Wayi, N

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Quality assessment of information systems in SMEs: a study of Eldoret, Kenya

    Quality assessment of information systems in SMEs: a study of Eldoret, Kenya by Ndiege, J.R.A., Wayi, N, Herselman, M E

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Quality Assessment of Information Systems in SMEs: A Study of Eldoret, Kenya

    Quality Assessment of Information Systems in SMEs: A Study of Eldoret, Kenya by Ndiege, J.R.A., Wayi, N., Herselman, M.E.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    P911: SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE AMONG PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) – FINDINGS FROM AN INTERNATIONAL IMCD PATIENT SURVEY

    P911: SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE AMONG PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) – FINDINGS FROM AN INTERNATIONAL IMCD PATIENT SURVEY by Shupo, F., Mason, N., Jones, E., Wayi‐Wayi, G., Repasky, M., Franklin, M., Brazier, J., Zibelnik, N., Mukherjee, S.

    Published in HemaSphere
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    PCR135 Symptom Burden and Its Impact on Daily Living with Idiopathic Multicentric Castleman’s Disease: Development and Psychometric Validation of a Bespoke International Patient and Caregiver Survey

    PCR135 Symptom Burden and Its Impact on Daily Living with Idiopathic Multicentric Castleman’s Disease: Development and Psychometric Validation of a Bespoke International Patient an... by Franklin, M, Jones, E, Shupo, F, Mason, N, Wayi-Wayi, G, Zibelnik, N, Repasky, M, Mukherjee, S, Brazier, JE

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    HTA168 Data Maturity and Treatment Positioning to Support Reimbursement: The Case for Siltuximab (SYLVANT®) in Australia

    HTA168 Data Maturity and Treatment Positioning to Support Reimbursement: The Case for Siltuximab (SYLVANT®) in Australia by Shupo, F, Abrams, K, Ademi, Z, Wayi-Wayi, G, Zibelnik, N, Kirchmann, M, Rutherford, C, Holko, P, Kawalec, P, Makarounas-Kirchmann, K

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: